Covered recipient · General Payments record
JULIAN J JAVIER
Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$16,412.34
42 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $15,000.00 | 1 |
| Food and Beverage | $1,412.34 | 41 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AngioDynamics, Inc. | $15,000.00 | 1 |
| Novartis Pharmaceuticals Corporation | $463.16 | 11 |
| Inari Medical, Inc. | $334.26 | 3 |
| Biosense Webster, Inc. | $123.35 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $87.33 | 5 |
| Bayer HealthCare Pharmaceuticals Inc. | $72.02 | 3 |
| Janssen Pharmaceuticals, Inc | $64.45 | 4 |
| PFIZER INC. | $58.95 | 4 |
| Amgen Inc. | $53.28 | 3 |
| AtriCure, Inc. | $29.31 | 1 |
| Boston Scientific Corporation | $28.22 | 1 |
| Alnylam Pharmaceuticals Inc. | $25.00 | 1 |
| Bard Peripheral Vascular, Inc. | $21.43 | 1 |
| Chiesi USA, Inc. | $19.81 | 1 |
| Philips Electronics North America Corporation | $19.54 | 1 |
| AstraZeneca Pharmaceuticals LP | $12.23 | 1 |
Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JULIAN J JAVIER
NPI 1013938331 · CMS profile ID 46222
Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology
NAPLES, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1013938331?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JULIAN J JAVIER, NPI 1013938331, CMS profile ID 46222. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013938331?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). JULIAN J JAVIER, NPI 1013938331, CMS profile ID 46222. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013938331?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- JULIAN J JAVIER, NPI 1013938331, CMS profile ID 46222, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1013938331?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
42 matching records · $16,412.34 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–42 of 42.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $13.58 | 12/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949530335 | CMS |
| PFIZER INC. | $14.47 | 12/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949461861 | CMS |
| Novartis Pharmaceuticals Corporation | $33.68 | 12/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893787053 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.04 | 12/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887662801 | CMS |
| Amgen Inc. | $12.08 | 11/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939466063 | CMS |
| Janssen Pharmaceuticals, Inc | $17.97 | 11/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885973113 | CMS |
| Amgen Inc. | $19.06 | 11/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939466061 | CMS |
| Novartis Pharmaceuticals Corporation | $166.24 | 11/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893787049 | CMS |
| Novartis Pharmaceuticals Corporation | $102.25 | 11/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893787045 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12.76 | 11/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887662803 | CMS |
| Chiesi USA, Inc. | $19.81 | 10/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 960798633 | CMS |
| Novartis Pharmaceuticals Corporation | $22.32 | 10/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893787255 | CMS |
| Boston Scientific Corporation | $28.22 | 10/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 916635679 | CMS |
| Janssen Pharmaceuticals, Inc | $15.43 | 09/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885973121 | CMS |
| Philips Electronics North America Corporation | $19.54 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945615883 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $28.65 | 08/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930322115 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.23 | 08/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920251755 | CMS |
| Amgen Inc. | $22.14 | 08/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939466059 | CMS |
| Novartis Pharmaceuticals Corporation | $22.82 | 08/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893787251 | CMS |
| Alnylam Pharmaceuticals Inc. | $25.00 | 07/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 926078975 | CMS |
| Novartis Pharmaceuticals Corporation | $23.57 | 07/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893787247 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13.57 | 07/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887662805 | CMS |
| Janssen Pharmaceuticals, Inc | $16.72 | 06/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885973127 | CMS |
| AngioDynamics, Inc. | $15,000.00 | 05/31/2022 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 906327419 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.49 | 05/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887662807 | CMS |
| Novartis Pharmaceuticals Corporation | $21.44 | 05/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893787243 | CMS |
| Inari Medical, Inc. | $296.06 | 05/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 959274241 | CMS |
| PFIZER INC. | $17.76 | 05/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949135601 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $21.50 | 05/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930033893 | CMS |
| PFIZER INC. | $13.14 | 04/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949112381 | CMS |
| AtriCure, Inc. | $29.31 | 04/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932210813 | CMS |
| Novartis Pharmaceuticals Corporation | $9.52 | 04/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893787235 | CMS |
| Novartis Pharmaceuticals Corporation | $19.45 | 04/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893787239 | CMS |
| Novartis Pharmaceuticals Corporation | $18.68 | 03/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893787041 | CMS |
| Janssen Pharmaceuticals, Inc | $14.33 | 03/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885973107 | CMS |
| Biosense Webster, Inc. | $123.35 | 03/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887038045 | CMS |
| Bard Peripheral Vascular, Inc. | $21.43 | 02/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 936033757 | CMS |
| Inari Medical, Inc. | $17.36 | 02/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 959274237 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.47 | 02/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887662809 | CMS |
| Inari Medical, Inc. | $20.84 | 02/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 959274233 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $21.87 | 02/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929956999 | CMS |
| Novartis Pharmaceuticals Corporation | $23.19 | 01/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893787231 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $756,135.24 | 21 |
| PY2024 | Recipient | $8,192.73 | 2 |
| PY2024 | Principal investigator | $381,084.38 | 10 |
| PY2023 | Principal investigator | $42,942.49 | 5 |
| PY2022 | Principal investigator | $69,643.14 | 4 |
| PY2021 | Principal investigator | $89,438.04 | 5 |
| PY2020 | Principal investigator | $148,803.32 | 9 |
| PY2019 | Principal investigator | $208,129.74 | 16 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
21 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $31,277.55 | 12/31/2025 | Non-covered Recipient Entity Advanced Research for Health Improvement, LLC | A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared with a Standard 3-dose Regimen in | No dispute reported | 06/30/2026 | 1232937970 |
| Principal investigator 1 | Eli Lilly and Company | $19,500.00 | 12/22/2025 | Non-covered Recipient Entity ADVANCED RESEARCH FOR HEALTH IMPROVEMENT LLC | A STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH PERIPHERAL ARTERY DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL. | No dispute reported | 06/30/2026 | 1187874137 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $83,252.98 | 12/15/2025 | Non-covered Recipient Entity Advanced Research for Health Improvement, LLC | A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared with a Standard 3-dose Regimen in | No dispute reported | 06/30/2026 | 1232937924 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity ADVNCD RSRCH FOR HLTH IMPRVMT | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220626877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity ADVNCD RSRCH FOR HLTH IMPRVMT | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220626875 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 10/29/2025 | Non-covered Recipient Entity ADVNCD RSRCH FOR HLTH IMPRVMT | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220994257 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $19,300.00 | 10/23/2025 | Non-covered Recipient Entity ADVANCED RESEARCH FOR HEALTH IMPROVEMENT LLC | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190308796 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity ADVNCD RSRCH FOR HLTH IMPRVMT | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220626873 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $30,423.20 | 09/24/2025 | Non-covered Recipient Entity ADVANCED RESEARCH FOR HEALTH IMPROVMENT LLC | A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) | No dispute reported | 06/30/2026 | 1185549913 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21,200.00 | 09/22/2025 | Non-covered Recipient Entity Advanced Research for Health Improvement, LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220815153 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 09/01/2025 | Non-covered Recipient Entity ADVNCD RSRCH FOR HLTH IMPRVMT | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220626865 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 09/01/2025 | Non-covered Recipient Entity ADVNCD RSRCH FOR HLTH IMPRVMT | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220626867 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 09/01/2025 | Non-covered Recipient Entity ADVNCD RSRCH FOR HLTH IMPRVMT | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220626869 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity ADVNCD RSRCH FOR HLTH IMPRVMT | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220626871 |
| Principal investigator 1 | Amgen Inc. | $5,308.00 | 03/25/2025 | Non-covered Recipient Entity ADVANCED RESEARCH FOR HEALTH IMPROVEMENT, LLC | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246638869 |
| Principal investigator 1 | Eli Lilly and Company | $6,097.21 | 01/27/2025 | Non-covered Recipient Entity MILLENNIUM PHYSICIAN GROUP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187885332 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $19,917.53 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESEARCH FOR HEALTH IMPROVEMENT LLC | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190308794 |
| Principal investigator 1 | Amgen Inc. | $56,473.43 | 01/16/2025 | Non-covered Recipient Entity ADVANCED RESEARCH FOR HEALTH IMPROVEMENT LLC | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246638867 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,198.67 | 01/15/2025 | Non-covered Recipient Entity ADVANCED RESEARCH FOR HEALTH IMPROVEMENT | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190310158 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $58,812.25 | 01/08/2025 | Non-covered Recipient Entity ADVANCED RESEARCH FOR HEALTH IMPROVMENT LLC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185549911 |
| Principal investigator 1 | Eli Lilly and Company | $395,372.77 | 01/07/2025 | Non-covered Recipient Entity ADVANCED RESEARCH FOR HEALTH IMPROVEMENT LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187875251 |